Thus, in allogeneic settings, an mTOR inhibitor such as Rapa is a better choice for adjunct therapy with IL-2 in expansion of Tregs and protection against allogeneic BMT-induced GVHD. The gene discussed is MTOR; the disease is graft versus host disease.